It was a good Thursday for GSK’s Jemperli (dostarlimab), as the immunotherapy received both full FDA approval in endometrial cancer and the regulatory go-ahead regarding its development plan in rectal cancer.
https://www.pharmalive.com/wp-content/uploads/2022/04/BioSpaceGSK4-27-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-02-10 10:40:512023-02-10 10:40:51FDA adcomm clears way for GSK's Jemperli in rectal cancer
